BV3.F Bavarian Nordic A/S

Healthcare Biotechnology Frankfurt Exchange
31.80 EUR
Close of Nov 12, 2026
22.60 34.30
Market cap
EUR 2.37B
P/E
12.2x
P/B
1.38x
ROE
11.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BV3.F undervalued?

Graham number
Price31.80
Graham value36.76
Discount13.5%

BV3.F trades 13.5% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bavarian Nordic A/S fundamental analysis

No fundamental analysis for Bavarian Nordic A/S yet.

Bavarian Nordic A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN …

Full company profile